AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30567603 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily text-message reminders on case management of malaria
Number of subjects: 50
Study 30567603 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily text-message reminders on case management of malaria, pneumonia, and diarrhoea
Number of subjects: 50
Study 30567603 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no text-message reminders)
Number of subjects: 50
Study 27418212 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized antithrombotic risk assessment tool (CARAT)
Number of subjects: 393
Study 27418212 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 393
Study 25058346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg BID plus standard dose of weekly paclitaxel
Number of subjects: 0
Study 22434159 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with ISB
Number of subjects: 61
Study 22434159 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with SSNB + ANB
Number of subjects: 61
Study 22434159 — intervention group
Group type: COMPARATOR
Intervention: PCA only
Number of subjects: 61
Study 20922265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program (walking three times a week for 13 weeks)
Number of subjects: 22
Study 20922265 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational lectures once a week)
Number of subjects: 22
Study 20922265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program
Number of subjects: 22
Study 20922265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 17030077 — intervention group
Group type: EXPERIMENTAL
Intervention: Active/cooperative instruction
Number of subjects: 0
Study 17030077 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based instruction
Number of subjects: 0
Study 18190273 — intervention group
Group type: EXPERIMENTAL
Intervention: Keepin' It Safe program
Number of subjects: 204
Study 18190273 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 204
Study 15207761 — intervention group
Group type: EXPERIMENTAL
Intervention: ibandronate therapy (6 or 12 mg)
Number of subjects: 20
Study 10731544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group
Number of subjects: 184
Study 10731544 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard support group
Number of subjects: 184
Study 10731544 — intervention group
Group type: COMPARATOR
Intervention: Routine care control group
Number of subjects: 184
Study 8957198 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband ultrasound attenuation in men (127.3 +/- 12.8 dB MHz-1)
Number of subjects: 217
Study 8957198 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of sound in men
Number of subjects: 217
Study 8957198 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband ultrasound attenuation values in men
Number of subjects: 217
Study 8957198 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of sound values in men
Number of subjects: 217
Study 8957198 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of sound values in women
Number of subjects: 217
Study 8957198 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband ultrasound attenuation and speed of sound values in men
Number of subjects: 217
Study 8957198 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband ultrasound attenuation and speed of sound values in women
Number of subjects: 217
Study 1306536 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglaucon (Clonidine hydrochloride) 15 microliters 0.125%
Number of subjects: 17
Study 1306536 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglaucon (Clonidine hydrochloride) 15 microliters 0.25%
Number of subjects: 17
Study 1306536 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglaucon (Clonidine hydrochloride) 15 microliters 0.50%
Number of subjects: 17
Study 1306536 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglaucon (Clonidine hydrochloride) 40 microliters 0.50%
Number of subjects: 17
Study 1306536 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglaucon (Clonidine hydrochloride) 40 microliters 0.125%
Number of subjects: 17
Study 1306536 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglaucon (Clonidine hydrochloride) 40 microliters 0.25%
Number of subjects: 17
Study 1306536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2857361 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen at 2 atmospheres absolute for 90 min daily for a total of 20 exposures
Number of subjects: 120
Study 2857361 — intervention group
Group type: COMPARATOR
Intervention: Normal air at normal pressure for a similar length of time
Number of subjects: 120
Study 31416741 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP algorithm for identifying periprosthetic femur fractures (PPFFx)
Number of subjects: 4520
Study 31416741 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP algorithm for determining Vancouver classification of PPFFx
Number of subjects: 4520
Study 27347862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-focused muscle strengthening treatment program
Number of subjects: 237
Study 27347862 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-focused muscle strengthening treatment program
Number of subjects: 237
Study 27347862 — intervention group
Group type: COMPARATOR
Intervention: All subjects (PFP and controls)
Number of subjects: 237
Study 26121708 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 842
Study 26121708 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 842
Study 23615144 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative beliefs about symptom management (SMBQ)
Number of subjects: 190
Study 23615144 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived negative attitudes from healthcare providers (CommA)
Number of subjects: 190
Study 23615144 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived communication difficulties (CommD)
Number of subjects: 190
Study 23615144 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 190
Study 22032247 — intervention group
Group type: EXPERIMENTAL
Intervention: EBQI applied to CCM implementation
Number of subjects: 546
Study 22032247 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-CCM)
Number of subjects: 546
Study 22032247 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC predilection to adopt CCM
Number of subjects: 546
Study 18814197 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver education and training intervention delivered over five, weekly, half‐hour sessions consisting of assessment, basic education about dementia, and training regarding specific problem behaviors.
Number of subjects: 60
Study 18814197 — intervention group
Group type: COMPARATOR
Intervention: Medical care as usual (Control group)
Number of subjects: 60
Study 16484875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg per day
Number of subjects: 978
Study 16484875 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 500 mg twice a day
Number of subjects: 978
Study 16484875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 978
Study 12941090 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hydroquinone‐cyclodextrin formulation applied once daily for 2 months
Number of subjects: 30
Study 12941090 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated forearm)
Number of subjects: 30
Study 10711913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (300 mg by mouth)
Number of subjects: 16
Study 9180438 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cardiac output (CCO) monitoring
Number of subjects: 38
Study 1609592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Hip screws
Number of subjects: 73
Study 1609592 — intervention group
Group type: COMPARATOR
Intervention: Gouffon screws
Number of subjects: 73
Study 3908046 — intervention group
Group type: EXPERIMENTAL
Intervention: Active alveolar expansion using an incentive spirometer
Number of subjects: 30
Study 31246555 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic handgrip (RHG; 1:1 duty cycle, 40% maximal voluntary contraction)
Number of subjects: 35
Study 31246555 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg cycling (17 ± 3% peak power output)
Number of subjects: 35
Study 31246555 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent exercise at the same intensities as RHG and cycling
Number of subjects: 35
Study 29982253 — intervention group
Group type: EXPERIMENTAL
Intervention: EA-230
Number of subjects: 180
Study 29982253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 27008287 — intervention group
Group type: COMPARATOR
Intervention: C-arm guided epidural injection of local anesthetic and corticosteroid
Number of subjects: 132
Study 27008287 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 international unit calcitonin added to the mixture of local anesthetic and corticosteroid
Number of subjects: 132
Study 24882173 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 79
Study 24882173 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 79
Study 24882173 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc analysis
Number of subjects: 79
Study 22444945 — intervention group
Group type: EXPERIMENTAL
Intervention: DQIP intervention (web-based informatics tool, outreach visit, fixed payment, and per patient review payment)
Number of subjects: 40
Study 22444945 — intervention group
Group type: EXPERIMENTAL
Intervention: DQIP intervention
Number of subjects: 40
Study 20060081 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 mug/day)
Number of subjects: 157
Study 20060081 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (10 mg/day)
Number of subjects: 157
Study 17366252 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions
Number of subjects: 491
Study 17366252 — intervention group
Group type: EXPERIMENTAL
Intervention: More outreach contacts
Number of subjects: 491
Study 17366252 — intervention group
Group type: EXPERIMENTAL
Intervention: Not being homeless
Number of subjects: 491
Study 17366252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer problems with alcohol
Number of subjects: 491
Study 17366252 — intervention group
Group type: EXPERIMENTAL
Intervention: More problems with drugs
Number of subjects: 491
Study 17366252 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemplation or determination stage of change
Number of subjects: 491
Study 16085693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (5 pmol/kg/min)
Number of subjects: 10
Study 16085693 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 11600532 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.3 mg
Number of subjects: 30
Study 11600532 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3.0 mg
Number of subjects: 30
Study 11600532 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.1 mg
Number of subjects: 30
Study 11600532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9875064 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrogenated fish oil (PHFO) margarine
Number of subjects: 16
Study 9875064 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil (VO) margarine
Number of subjects: 16
Study 8021413 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeezable cleft palate nurser
Number of subjects: 31
Study 8021413 — intervention group
Group type: COMPARATOR
Intervention: Crosscut nipple
Number of subjects: 31
Study 2723107 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8
Study 2723107 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 8
Study 31808657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative acupuncture (AC)
Number of subjects: 99
Study 31808657 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthesia care (SC)
Number of subjects: 99
Study 31808657 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of AC vs SC
Number of subjects: 99
Study 30374965 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment
Number of subjects: 0
Study 30374965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28592571 — intervention group
Group type: EXPERIMENTAL
Intervention: Full internet-based aural rehabilitation (n=37)
Number of subjects: 74
Study 28592571 — intervention group
Group type: COMPARATOR
Intervention: One element of the internet-based aural rehabilitation (control group, n=37)
Number of subjects: 74
Study 25003623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (individual home exercise program) for 12 weeks
Number of subjects: 122
Study 22949577 — intervention group
Group type: EXPERIMENTAL
Intervention: osmotic‐release oral system methylphenidate (OROS‐MPH) + transdermal nicotine replacement + brief cessation counseling
Number of subjects: 255
Study 22949577 — intervention group
Group type: COMPARATOR
Intervention: placebo + transdermal nicotine replacement + brief cessation counseling
Number of subjects: 255
Study 21939534 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent proximal pin placement (Group A)
Number of subjects: 70
Study 21939534 — intervention group
Group type: COMPARATOR
Intervention: Parallel proximal pin placement (Group B)
Number of subjects: 70
Study 18791983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group psychotherapy in combination with open methylphenidate treatment (Medikinet retard ®) titrated upward individually until the maximum dose of 1.3 mg/kg/day
Number of subjects: 144
Study 18791983 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling
Number of subjects: 144
Study 16548956 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac‐Hand group (diclofenac transdermal patch on the dorsum of hand and placebo patch on the buttock)
Number of subjects: 72
Study 16548956 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac‐Buttock group (placebo patch on the dorsum of the hand and diclofenac transdermal patch on the buttock)
Number of subjects: 72
Study 16548956 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo adhesive patch on both the dorsum of hand and the buttock)
Number of subjects: 72
Study 14641393 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit and booklet education
Number of subjects: 120
Study 14641393 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 11060685 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 0
Study 9040687 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal carotid peak systolic velocity (IPSV)
Number of subjects: 0
Study 9040687 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal carotid end‐diastolic velocity (IEDV)
Number of subjects: 0
Study 9040687 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSV/CEDV ratio
Number of subjects: 0
Study 9040687 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid peak systolic velocity (CPSV)
Number of subjects: 0
Study 9040687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratios of IPSV/CEDV and IEDV/CEDV
Number of subjects: 0
Study 7717053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 50
Study 7717053 — intervention group
Group type: COMPARATOR
Intervention: Control (no ketorolac tromethamine)
Number of subjects: 50
Study 2908720 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol 400 mg
Number of subjects: 20
Study 2908720 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 20 mg
Number of subjects: 20
Study 2908720 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 30787294 — intervention group
Group type: EXPERIMENTAL
Intervention: RV144 HIV vaccine
Number of subjects: 263
Study 30787294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 30089018 — intervention group
Group type: EXPERIMENTAL
Intervention: Bingocize® (Bingo + Health Education + Exercise)
Number of subjects: 100
Study 30089018 — intervention group
Group type: COMPARATOR
Intervention: Control (Bingo + Health Education)
Number of subjects: 100
Study 27468593 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine (5%)
Number of subjects: 20
Study 27468593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (1.60 mg/mL)
Number of subjects: 20
Study 27468593 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 25245482 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Swallowing (TS) therapy
Number of subjects: 29
Study 25245482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NMES/TS therapy
Number of subjects: 29
Study 25245482 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal neuromuscular electrical stimulation (NMES) therapy
Number of subjects: 29
Study 25245482 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study 22989795 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (n=81)
Number of subjects: 261
Study 22989795 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=43)
Number of subjects: 261
Study 22989795 — intervention group
Group type: COMPARATOR
Intervention: Best Standard of Care (BSC) group (n=137)
Number of subjects: 261
Study 19296100 — intervention group
Group type: EXPERIMENTAL
Intervention: MACT of the ankle joint
Number of subjects: 22
Study 17265406 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for bacterial pneumonia (specifics not provided)
Number of subjects: 0
Study 17265406 — intervention group
Group type: COMPARATOR
Intervention: Hospital's pneumonia care plan (not specified)
Number of subjects: 0
Study 15041701 — intervention group
Group type: EXPERIMENTAL
Intervention: 25000 IU/day vitamin A
Number of subjects: 129
Study 15041701 — intervention group
Group type: EXPERIMENTAL
Intervention: 50000 IU/day vitamin A
Number of subjects: 129
Study 15041701 — intervention group
Group type: EXPERIMENTAL
Intervention: 75000 IU/day vitamin A
Number of subjects: 129
Study 15041701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 12428086 — intervention group
Group type: EXPERIMENTAL
Intervention: DX-9065a (1 mg bolus + 0.25 mg/h x 2 h, followed by 1 mg bolus + 0.625 mg/h x 2 h, and a final 1 mg bolus + 1.25 mg/h x 2 h)
Number of subjects: 6
Study 12428086 — intervention group
Group type: EXPERIMENTAL
Intervention: DX-9065a + ASA (pre-treatment)
Number of subjects: 6
Study 12428086 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin + ASA (1 mg/Kg s. c + 162 mg/day x 3 days)
Number of subjects: 6
Study 9454525 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg/d
Number of subjects: 93
Study 9454525 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg/d
Number of subjects: 93
Study 9454525 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 200 mg/d
Number of subjects: 93
Study 9454525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 8578993 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (Cf, 50 mg/g of ointment or solution)
Number of subjects: 115
Study 8578993 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN, 5 x 10(4) IU/g)
Number of subjects: 115
Study 8578993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of Caffeine and Interferon (same concentrations)
Number of subjects: 115
Study 8578993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 2236825 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-lactam and aminoglycoside
Number of subjects: 102
Study 2236825 — intervention group
Group type: EXPERIMENTAL
Intervention: vancomycin (added after 48 hours)
Number of subjects: 102
Study 2236825 — intervention group
Group type: EXPERIMENTAL
Intervention: amphotericin B (added after 96 hours)
Number of subjects: 102
Study 365543 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20
Study 365543 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 20
Study 7237896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen (TCNF)
Number of subjects: 0
Study 7237896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 7237896 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with either diuretic
Number of subjects: 0
Study 7237896 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol alone
Number of subjects: 0
Study 7237896 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 31155431 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 31
Study 31155431 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Number of subjects: 31
Study 31155431 — intervention group
Group type: COMPARATOR
Intervention: Control group (fixed resistance expiratory muscle training)
Number of subjects: 31
Study 31507249 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 143
Study 31507249 — intervention group
Group type: COMPARATOR
Intervention: Other medications for gout treatment
Number of subjects: 143
Study 31507249 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 143
Study 31507249 — intervention group
Group type: COMPARATOR
Intervention: Untreated gout patients
Number of subjects: 143
Study 27260298 — intervention group
Group type: EXPERIMENTAL
Intervention: PriMa intervention group
Number of subjects: 100
Study 27260298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 26274840 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 19
Study 26274840 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 19
Study 24370353 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 with cetuximab
Number of subjects: 302
Study 24370353 — intervention group
Group type: COMPARATOR
Intervention: UFOX with cetuximab
Number of subjects: 302